Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR‐34a‐5p/PD‐L1 axis

Author:

He Tingting1,Huang Jintao1,Liang Hansi2,Zhong Binyan1,Xu Guili1ORCID,Zhu Xiaoli1

Affiliation:

1. Department of Interventional Radiology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China

2. Jiangsu Institute of Clinical Immunology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China

Abstract

AbstractCircular RNAs (circRNAs) may be involved in tumorigenesis. Recently, the role of circRNAs in hepatocellular carcinoma (HCC) has drawn wide attention. Herein, we aimed to explore the regulation and function of hsa_circ_0005239 in the malignant biological behavior and angiogenesis of HCC, as well as the link between hsa_circ_0005239 and programmed cell death ligand 1 (PD‐L1) in HCC. Quantitative real‐time polymerase chain reaction (qRT‐PCR) assays revealed that hsa_circ_0005239 was upregulated in HCC tumor samples and cell lines. Furthermore, a series of in vitro and in vivo assays explored the effects of hsa_circ_0005239 on biological processes involved in the development of HCC. Knockdown of hsa_circ_0005239 significantly inhibited cell migration, cell invasion, and angiogenesis in HCC, while overexpression showed the opposite effect. In the in vivo assays, hsa_circ_0005239 downregulation suppressed the growth of xenograft tumors in nude mice, which supported that hsa_circ_0005239 is a tumor promoter in HCC. Mechanistically, hsa_circ_0005239 binds to miR‐34a‐5p and functions as a competing endogenous RNA to modulate the expression of PD‐L1. Further experiments revealed that the hsa_circ_0005239/PD‐L1 axis regulates the malignant phenotypes of HCC cells through the phosphoinositide‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway. These results revealed the role of hsa_circ_0005239 and the hsa_circ_0005239/miR‐34a‐5p/PD‐L1 axis in HCC, providing a potential diagnostic biomarker and therapeutic target for HCC.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The current status and future of PD-L1 in liver cancer;Frontiers in Immunology;2023-12-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3